Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VEGFR1-1084 + VEGFR2-169
- Development stage
- Unknown
- Lead developer
- Fukushima Medical University
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
VEGFR1-1084 + VEGFR2-169 is a bivalent cancer vaccine developed by Fukushima Medical University for the treatment of pancreatic cancer. It consists of two HLA-A*2402-restricted epitope peptides derived from Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) and Receptor 2 (VEGFR2). The vaccine is designed to stimulate the immune system to produce cytotoxic T lymphocytes (CTLs) that specifically target and destroy endothelial cells in the tumor vasculature, thereby inhibiting angiogenesis and tumor growth. In clinical trials, it is typically emulsified with the adjuvant Montanide ISA 51 and administered in combination with chemotherapy, such as gemcitabine, to patients with unresectable, recurrent, or metastatic pancreatic cancer.
- Other names
- VEGFR1/VEGFR2 peptide vaccineAntiangiogenic vaccine therapy
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)HLA-A*24 (Major histocompatibility complex class I molecule presenting MAGE-A4 peptide)
Beyond the preview
Go deeper on VEGFR1-1084 + VEGFR2-169.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VEGFR1-1084 + VEGFR2-169.